GS15-4, “the 21st Century Ginseng Extract”, is a unique technology (patents-pending) using enzyme fermentation to produce a completely balanced ginseng extract in its end-stage metabolite form. Human clinical studies have proven that it provides 15 times higher absorption, four times faster absorption and four times more consistent absorption.
“Ilhwa is excited to establish this partnership with RFI,” said David C. Konn, president of Ilhwa North America. “RFI is a rare company that has created true vertical integration in the natural ingredient market. As the world leader in ginseng science, Ilhwa wanted to find the right partner to work with on this breakthrough in ginseng technology.”
“GS15-4 is a great fit with our current product line, especially our energy, stress and fermented product platforms,” said Jeff Wuagneux, president and CEO of RFI. “In addition, Ilhwa’s single passion for ginseng, its strong clinical science and its high quality manufacturing exemplify RFI’s From Field to Formula motto.”